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Reply to Retrospective
evaluation of cetuximab-related
adverse events from claims
databases—methodological
concerns
Maier et al. [1] questioned the algorithm we applied to
identify infusion reactions (IRs) associated with cetuximab
using claims data and the appropriateness of comparing
rates of IRs from a claims data analysis with those of clinical
trials.
Because there is no International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation diagnosis code for IRs,
we identiﬁed IRs based on IR-related diagnoses, procedures and
medications indicative of medical interventions that would be
associated with treatment of an IR. The algorithm was fully
described in the methods section of the paper and where
necessary, we cited the limitations of the algorithm. The rate of
IRs requiring medical intervention in this study was 8.4%,
which is consistent with the 7% reported by Schwartzberg et al.
[2], and much lower than the 22% reported by O’Neil et al. [3]
using clinical trial data. Furthermore, all-grade IRs are
reported in the USA prescribing information for cetuximab
as 15%–21%, and the rate of severe reactions are reported as
2%–5%. Given that clinical trials generally study a population
that is not completely representative of the general population
with colorectal cancer (CRC), it is entirely plausible that the
rates we observed are reasonable for the general CRC
population.
Maier et al. [1] also commented that the rate of IRs during
the initial infusion is lower in our study relative to the rate
reported in the USA prescribing information for cetuximab.
However, the rates reported in our study are consistent with
other published literature. More speciﬁcally, Needle [4]
reported that 33% of patients with severe IRs experienced
events after their second dose of cetuximab. Lenz [5] also noted
that 10%–30% of IRs to monoclonal antibodies are delayed and
occur in later infusions. Differences in patient management
between the clinical trial setting and routine clinical practice
might contribute to the different ﬁndings.
In summary, the ﬁndings from our study are consistent with
other published literature. Using claims data, as we did in our
study, provides information about real world clinical practice,
and reﬂects the general population of patients with a given
condition.
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